A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PV / polycythemia vera

[Related PubMed/MEDLINE]
Total Number of Papers: 1321
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PV  (>> Co-occurring Abbreviation)
Long Form:   polycythemia vera
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2015 Anagrelide hydrochloride and ruxolitinib for treatment of polycythemia vera. HU
2015 Aspirin-responsive, migraine-like transient cerebral and ocular ischemic attacks and erythromelalgia in JAK2-positive essential thrombocythemia and polycythemia vera. ET, MIAs
2015 Association of the ACE I/D gene polymorphisms with JAK2V617F-positive polycythemia vera and essential thrombocythemia. CG, CI, ET, OR, TG
2015 BCR-ABL negative myeloproliferative neoplasia: a review of involved molecular mechanisms. ET, Ph- MPN, PMF
2015 CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable. APMF, ET, MPN-U, MPNs, PMF
2015 Calreticulin exon 9 mutations in myeloproliferative neoplasms. CALR, ET, JAK2, MPL, MPNs, PMF
2015 Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond. CALR, cloud-like, ECMP, EMGM, ET, MF, MPN, PMGM, PVSG
2015 Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. ET, JAK2, MPNs, Ph, PMF
2015 Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia. ET, MF
10  2015 Coronary microvascular dysfunction due to essential thrombocythemia and policythemia vera: the missing piece in the puzzle of their increased cardiovascular risk? CAD, CFR, ET
11  2015 Current and future treatment options for polycythemia vera. JAK2
12  2015 Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis. ET, MPNs, PMF, SVT
13  2015 Distribution of lymphocyte subpopulations in patients with polycythemia vera. NK
14  2015 Dysregulation of the MIRLET7/HMGA2 axis with methylation of the CDKN2A promoter in myeloproliferative neoplasms. 3'UTR, ET, HMGA2, MPNs, PMF
15  2015 Endovascular stent graft repair of thoracic aortic mural thrombus in a patient with polycythemia vera: a word of caution. TAMT
16  2015 Flow cytometry immunophenotypic analysis of philadelphia-negative myeloproliferative neoplasms: Correlation with histopathologic features. BM, ET, FCI, MDS, MPN, MPN-U, PMF
17  2015 From Philadelphia-Negative to JAK2-Positive: Effect of Genetic Discovery on Risk Stratification and Management. ET, MF, MPNs, Ph
18  2015 Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression. AML, CMML, CN-LOH, ET, MC, MDS/MPN, MF, MPN, MPN-U, SNP-A
19  2015 Impact of bone marrow pathology on the clinical management of Philadelphia chromosome-negative myeloproliferative neoplasms. ET, JAK, MF, PMF
20  2015 Influence of the JAK2 V617F Mutation and Inherited Thrombophilia on the Thrombotic Risk among Patients with Myeloproliferative Disorders. ET, PMI, RR
21  2015 Limitations of fibrosis grade as diagnostic criteria for post polycythemia vera and essential thrombocytosis myelofibrosis. ET, MF, MPNs, PMF
22  2015 Long-term outcome of liver transplant patients with Budd-Chiari syndrome secondary to myeloproliferative neoplasms. AML, BCS, ET, MPN, OLT, PMF
23  2015 Massive intracardiac thrombosis during coronary artery bypass grafting surgery. ---
24  2015 Matrix Metalloproteinases 2 and 9 Polymorphism in Patients With Myeloproliferative Diseases: A STROBE-Compliant Observational Study. ECM, ET, MMPs, SP
25  2015 Mechanisms of thrombogenesis in polycythemia vera. ---
26  2015 Microarray and Proteomic Analyses of Myeloproliferative Neoplasms with a Highlight on the mTOR Signaling Pathway. ET, MPNs, PMF
27  2015 MicroRNA Expression Analysis in Patients with Primary Myelofibrosis, Polycythemia vera and Essential Thrombocythemia. ET, miRNA, PMF
28  2015 MMP2 gene-735 C/T and MMP9 gene -1562 C/T polymorphisms in JAK2V617F positive myeloproliferative disorders. ET, MMPs, MPDs, PCR-RFLP
29  2015 Molecular genetic evaluation of myeloproliferative neoplasms. CML, ET, MPNs, PMF
30  2015 Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b. IFN-alpha
31  2015 Myeloproliferative and thrombotic burden and treatment outcome of thrombocythemia and polycythemia patients. ET, MPN-T
32  2015 Myeloproliferative Neoplasms: A Contemporary Review. ASXL1, CALR, ET, JAK2, MPL, PMF
33  2015 Neutrophilic progression in a case of polycytemia vera mimicking chronic neutrophilic leukemia: clinical and molecular characterization. ---
34  2015 New Therapeutic Approaches in Polycythemia Vera. JAK
35  2015 No increase of JAK2 46/1 haplotype frequency in essential thrombocythemia with CALR mutations: Functional effect of the haplotype limited to allele with JAK2V617F mutation but not CALR mutation. ET, MPN
36  2015 Novel and emerging therapies for the treatment of polycythemia vera. ---
37  2015 Nuclear factor-erythroid 2, nerve growth factor receptor, and CD34-microvessel density are differentially expressed in primary myelofibrosis, polycythemia vera, and essential thrombocythemia. ET, HPF, NF-E2, NGFR
38  2015 Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia. ET, VKA
39  2015 Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis. ---
40  2015 Perioperative blood product administration and thromboembolic events in patients with treated polycythemia vera: a case-control study. CI, OR
41  2015 Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. AVWS, CALR, ET, JAK2, MPL
42  2015 Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden. ET
43  2015 Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms. ET, IM, miRs, MPNs
44  2015 Ruxolitinib for the treatment of patients with polycythemia vera. ---
45  2015 Target hematologic values in the management of essential thrombocythemia and polycythemia vera. ET
46  2015 The mutation profile of JAK2, MPL and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasms. CALR, ET, MF, MPN
47  2015 The Prevalence of JAK2, MPL, and CALR Mutations in Chinese Patients With BCR-ABL1-Negative Myeloproliferative Neoplasms. MPNs
48  2015 Up-regulation of MicroRNA 146b is Associated with Myelofibrosis in Myeloproliferative Neoplasms. CALR, ET, JAK2, MF, miR, miRNA, MPN, PMF
49  2015 [Analysis of CALR, JAK2 and MPL gene mutations in BCR-ABL negative myeloproliferative neoplasms]. ET, MPN, PMF
50  2015 [Clinical analysis of 70 cases of polycythemia vera]. LDH
51  2015 [Clinical feature and prognosis analysis of elderly patients with polythemia vera]. ---
52  2015 [JAK2 V617F mutation burden and its clinical implications in 415 patients with myeloproliferative neoplasm]. ET, MPN, PMF
53  2015 [Research progress of myeloproliferative neoplasms]. allo-ASCT, ET, MPN, PMF
54  2015 [Survival and prognosis of patients with polycythemia vera: a study of 816 patients in a single Chinese center]. AML, IFN-alpha, OS, post-PV MF, SMR, WBC
55  2014 A highly specific q-RT-PCR assay to address the relevance of the JAK2WT and JAK2V617F expression levels and control genes in Ph-negative myeloproliferative neoplasms. ASO, B2M, ET, GUSB, PLTs, PMF
56  2014 A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. ET, mPV, WHO
57  2014 A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. JAK2
58  2014 Abnormal adhesion of red blood cells in polycythemia vera: a prothrombotic effect? MPN
59  2014 Analysis of the Ten-Eleven Translocation 2 (TET2) gene mutation in myeloproliferative neoplasms. ET, MPNs, TET2
60  2014 Angiogenic activity in the sera of patients with post-kidney transplant erythrocytosis. PTE, VEGF
61  2014 Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women's Health Study cohort. ET, MF, MPNs
62  2014 Antiplatelet therapy in the management of myeloproliferative neoplasms. ASA, ECLAP, ET
63  2014 Application of the optimized CO-rebreathing method for determination of hemoglobin mass in patients with polycythemia vera. BSA, LBM, RCV
64  2014 Assessing disease burden in patients with classic MPNs. ET, MF, MPN
65  2014 Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. CHR, ET
66  2014 Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases. CVT, ET, MPNs, PMF
67  2014 Chorea disclosing a polycythemia vera. JAK2
68  2014 Chronic myeloproliferative diseases. ET, PMF
69  2014 Circulating YKL-40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state. ET, MPN
70  2014 Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat. ET
71  2014 Cluster-like headache responsive to phlebotomy. ---
72  2014 Coexistence of myeloproliferative neoplasm and plasma-cell dyscrasia. ET, MGUS, MM, MPNs, PMF
73  2014 Complex karyotype in a polycythemia vera patient with a novel SETD1B/GTF2H3 fusion gene. EEC, PVSG
74  2014 Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications. ET, IL, JAK2, MPNs
75  2014 Determination of accuracy of polycythemia vera diagnoses and use of the JAK2V617F test in the diagnostic scheme. EMR, MPN
76  2014 Differential sensitivity to JAK inhibitory drugs by isogenic human erythroblasts and hematopoietic progenitors generated from patient-specific induced pluripotent stem cells. iPSCs
77  2014 Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. DIPSS, ET, MF, MPNs
78  2014 Dkk3 levels in patients with myeloproliferative neoplasms. DKK3, ET, MPN, PMF
79  2014 Elevated levels of mast cells are involved in pruritus associated with polycythemia vera in JAK2V617F transgenic mice. ---
80  2014 Elevated serum erythropoietin in a patient with polycythaemia vera presenting with Budd-Chiari syndrome. EPO, JAK2
81  2014 Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. ET, MF, MPN, PMF
82  2014 Epidemiology of myeloproliferative neoplasms in the United States. ET, MF, MPNs
83  2014 Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter. BM, ET, MPN, Ph-neg, PMF, WHO
84  2014 Essential thrombocythemia: Rare cause of chorea. ET, MPD
85  2014 Health resource utilization and cost associated with myeloproliferative neoplasms in a large United States health plan. ET, HRU, MF, MPN
86  2014 Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm. GP, MPN
87  2014 How common are myeloproliferative neoplasms? A systematic review and meta-analysis. ET, MPNs, PMF
88  2014 How I treat polycythemia vera. ---
89  2014 Interferon alpha-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation. ET, HU, OHR
90  2014 Interferon apha 2b for treating patients with JAK2V617F positive polycythemia vera and essential thrombocytosis. ET, IFN
91  2014 Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis? MF, MPNs
92  2014 It is time to change thrombosis risk assessment for PV and ET? ET
93  2014 Jak-2 positive myeloproliferative neoplasms. CEL-NOS, CML, CNL, ET, MPNs, PMF, TKIs
94  2014 JAK2 V617F mutation status of 232 patients diagnosed with chronic myeloproliferative neoplasms. CMPNs, ET, JAK2, PMF
95  2014 JAK2V617F allele burden in patients with myeloproliferative neoplasms. ARMS-PCR, ET, MF, MPNs, RQ-PCR
96  2014 JAK2V617F allele burden is associated with thrombotic mechanisms activation in polycythemia vera and essential thrombocythemia patients. ET, PLA, TF
97  2014 JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease. ET, UPD
98  2014 JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events. ET, IRR
99  2014 JAK2V617F mutation and endogenous erythroid colony formation in patients with polycythaemia vera. Agar-LCM, AS-PCR, EEC, EPO, WHO
100  2014 JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan. MPNs, RCM